What is the difference between ARA-290 and Cerebrolysin?

ARA-290 (ARA-290 (Cibinetide)) is graded B and is Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy. Cerebrolysin (Cerebrolysin (porcine brain peptide complex)) is graded B and is Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia. They are commonly compared because they share the categories: neuroprotection.

Which has stronger clinical evidence — ARA-290 or Cerebrolysin?

On our internal evidence scale, ARA-290 is B and Cerebrolysin is B. A+ indicates large RCTs plus FDA approval; C indicates primarily preclinical or anecdotal evidence.

What is the typical dose of ARA-290 vs Cerebrolysin?

ARA-290: Trial range: 1–4 mg subcutaneous daily. Cerebrolysin: Trial range: 5–30 mL daily (intravenous infusion). Always work with a licensed clinician — peptide dosing should be individualized.

ARA-290 vs Cerebrolysin

Both ARA-290 and Cerebrolysin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.

ARA-290

Evidence B

ARA-290 (Cibinetide)

An 11-amino-acid peptide derived from the helix-B region of erythropoietin. Activates the tissue-protective receptor without erythropoietic side effects. Investigated for neuropathy and inflammation.

View full ARA-290 profile →

Cerebrolysin

Evidence B

Cerebrolysin (porcine brain peptide complex)

A standardized mixture of low-molecular-weight peptides from porcine brain. Decades of stroke, dementia, and TBI trial data — modest but consistent cognitive recovery effects.

View full Cerebrolysin profile →

Side-by-Side

Attribute	ARA-290	Cerebrolysin
Evidence Grade	B	B
FDA Status	Not FDA-approved — Phase 2/3 trials for sarcoidosis-associated small fiber neuropathy	Not FDA-approved in US — approved in 50+ countries for stroke, traumatic brain injury, and dementia
Typical Dose	Trial range: 1–4 mg subcutaneous daily	Trial range: 5–30 mL daily (intravenous infusion)
Clinics Indexed	9	41
Categories	anti-inflammatory, neuroprotection	cognitive, neuroprotection

Key reported benefits — ARA-290

✓Small-fiber neuropathy improvement
✓Anti-inflammatory
✓No erythrocytosis

Key reported benefits — Cerebrolysin

✓Stroke recovery support
✓TBI rehabilitation
✓Cognitive function in dementia

Educational use only

This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.

← Back to all comparisons